Improving Outcomes in Colorectal Cancer Screening

Jessica Jamison, MPH Sr. Director Primary Care Systems American Cancer Society

THE OFFICIAL SPONSOR OF BIRTHDAYS.



The Scope of Colorectal Cancer

Estimated new cases, 2016

California, by cancer type

Breast (female)				
		26,730		
Lung and bronchus				
	18,140			
Prostate				
	17,240			
Colorectum				
13,77	0			
Melanoma of the skin				
8,560				
Non-Hodgkin lymphoma				
7,760				
EXPAND TO SEE ALL DATA				

American Cancer Society, 2016

Estimated deaths, 2016

California, by cancer type

Lung and bro	nchus	
		12,230
Colorectum		
	5,180	
Breast (fema	le)	
	4,400	
Pancreas		
	4,390	
Liver and intr	ahepatic bile duct	
3	,600	
Prostate		
3,0	50	
EXPAND TO S	SEE ALL DATA	

American Cancer Society, 2016

EIGHTYBY2018 To join this effort visit www.nccrt.org

Trends in CRC incidence and mortality

Research suggests that observed declines in incidence and mortality are due in large part to:

- CRC treatment advances
- Screening → detecting cancers at earlier, more treatable stages
- Screening and polyp removal, preventing progression of polyps to invasive cancers
 - NEJM study Feb 2012 showed polyp removal associated with 53% lower risk of CRC death




Figure 3. Colorectal Cancer Incidence (2009-2013) and Mortality (2010-2014) Rates by Race/Ethnicity and Sex, US

AN: Alaska Native; AI: American Indian, excluding Alaska. Rates are age-adjusted to the 2000 US standard population. *Statistics based on data from Contract Health Service Delivery Area (CHSDA) counties; incidence rates exclude data from Kansas.

Sources: Incidence – North American Association of Central Center Registries (NAACCR), 2016; Alaska Natives only – Surveillance, Epidemiology, and End Results (SEER) Program, 2016. Mortality – National Center for Health Statistics, Centers for Disease Control and Prevention, 2016.


©2017 American Cancer Society, Inc., Surveillance Research




THE OFFICIAL SPONSOR OF BIRTHDAYS.



Non-Modifiable Risk Factors



Age: the most impactful risk factor



CRC screening should begin at age 50 for most people, earlier for those with a family history.


Modifiable risk factors



Modifiable Risk Factors

- Smoking increases risk of CRC by 18%
- Alcohol increases risk of CRC 41%
- Obesity increases risk of CRC 45%
- Diet
 - High intake (>60gm/day) of red, grilled or processed meat increases risk of CRC 35%
 - High intake of fiber DECREASES risk of CRC
 - Dietary supplements no effect, but food with folate and Vit D/Calcium may decrease risk

National Cancer Institute http://www.cancer.gov/cancertopics/pdq/prevention/colorectal/HealthPro fessional/page2



THE OFFICIAL SPONSOR OF BIRTHDAYS.





There are two aims of screening:

1. Prevention

Find and remove polyps to prevent cancer

2. Early Detection

Find cancer in the early stages, when best chance for a cure

STAGES OF COLON CANCER



IN SITU

Most colon cancers develop formed, but is from these noncancerous growths

POLYP

Cancer has not yet growing inside the colon or rectum walls

LOCAL

Cancer is now growing in the colon or rectum walls; nearby tissue unaffected

REGIONAL

Growth beyond the colon or rectum walls and into tissue or lymph nodes


DISTANT

Cancer has spread to other parts of the body such as liver or lungs




Benefits of Screening

Survival Rates by Disease Stage*



Screening Rates



Colorectal Cancer Screening* (%), in Adults 50 Years and Older, 2014


*A fecal occult blood test within the past year, or sigmoidoscopy within the past five years or colonoscopy within the past 10 years. Note: The colorectal cancer screening prevalence estimates do not distinguish between examinations for screening and diagnosis. **Source:** Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System, 2014. Public use data file.

CRC screening in CA IHS Community Health Centers

GPRA- 2015
 Colorectal Cancer
 Screening Rate 31.2%

UDS- 2015
 Colorectal Cancer
 Screening rate for
 CA FQHC's –
 41.2%





SOURCE: Behavioral Risk Factor Surveillance System, 2012



Screening Tests

ACS Screening Guidelines

- Options for Average risk adults age 50 and older:
 - **Colonoscopy** every 10 years, or
 - Flexible sigmoidoscopy (FSIG) every 5 years, or
 - Double contrast barium enema (DCBE) every 5 years, or
 - **CT colonography** (CTC) every 5 years
 - Guaiac-based fecal occult blood test (gFOBT) with high test sensitivity for cancer every year
 - Fecal immunochemical test (FIT) with high test sensitivity for cancer every year



USPSTF Recommendations

Population	Recommendation	Grade (What's This?)
Adults aged 50 to 75 years	The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years. The risks and benefits of different screening methods vary. See the Clinical Considerations section and the Table for details about screening strategies.	A
Adults aged 76 to 85 years	 The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient's overall health and prior screening history. Adults in this age group who have never been screened for colorectal cancer are more likely to benefit. Screening would be most appropriate among adults who 1) are healthy enough to undergo treatment if colorectal cancer is detected and 2) do not have comorbid conditions that would significantly limit their life expectancy. 	С



Recommended Screening Tests ACS and USPSTF


- Colonoscopy
- High Sensitivity Fecal Occult Blood Testing
 - Guaiac
 - Immunochemical
- Flexible Sigmoidoscopy (FSIG)
 - Recent studies support efficacy
 - Availability extremely limited in U.S.

Why Colonoscopy is NOT gold standard

- Evidence does not support "best test" or "gold standard"
- Greater patient requirements for successful completion
- Access
- Patient preference



Patient Preferences



Inadomi, Arch Intern Med 2012

Stool Tests

- Look for hidden blood in stool
- Two major types (but multiple brands)



Stool Test: Guaiac



- Most common type in U.S.
- Best evidence (3 RCT's)
- Need specimens from 3 bowel movements
- Non-specific
- Results influenced by foods and medications
- Older forms (Hemoccult II) have unacceptably low sensitivity
- Better sensitivity with newer versions (Hemoccult Sensa)

Stool Test: Immunochemical (FIT)

- Specific for <u>human blood</u> and for <u>lower GI bleeding</u>
- Results not influenced by foods or medications
- Some types require only 1 or 2 stool specimens
- Higher sensitivity than older forms of guaiac-based FOBT
- Slightly more costly than guaiac tests






FIT use in the US will likely increase due to recent elimination of guaiac-based testing by LabCorp and Quest Labs

Stool Testing Quality Issues

In-office FOBT is essentially worthless as a screening tool for CRC and should never be used for this purpose.



Summary - Stool Testing

- In-office FOBT is essentially worthless as a screening tool for CRC and should never be used.
- CRC screening by FOBT should be performed with high-sensitivity FOBT - either FIT or a highly sensitive gFOBT (such as Hemoccult SENSA).
 - Older, less sensitive guaiac tests (such as Hemoccult II) should not be used for CRC screening.
- Annual testing
- All positive screening tests should be evaluated by colonoscopy

Conclusion and Resources

THE OFFICIAL SPONSOR OF BIRTHDAYS.



How We Work with Primary Care Systems


- Focus on cancer prevention and early detection to support the work that you are already doing and identify any gaps that we can help support.
- We're here as a resource and as consultants on the following:
 Colon Cancer Breast Cancer Cervical Cancer HPV Vaccination Physical Activity Nutrition

*Our goal is to ensure your patients stay healthy and informed and that your cancer screening rates are at an optimum.

How We Work with

Primary Care Systems

Assistance with implementing recommended



of Task Force findings and recommendations on cancer screening. Click on each topic area to find results from the systematic reviews, included studies, evidence gaps, and journal publications.

The Centers for Disease Control and Prevention provides administrative, research, and technical support for the Community Preventive Services Task Force.

EBIs.

American Cancer Society and Primary Care Systems

Partners in Saving Lives




Recommended Evidence Based Interventions for Cancer Screening and How the American Cancer Society Can Help

Intervention Strategy	Support from the	
	American Cancer Society	
Client Reminders	Co-branded Screening Reminder	
	Postcards, Telephone Reminder	
	Scripts, Reminder Letter Templates	
Small Media	Patient Education Materials, DVDs,	
	Co-branded Posters	
Group Education	Patient Education Materials	
One-on-one Education	CHW E-learning Modules, Patient	
	Education Materials, Physician	
	Speakers to Educate Staff	
Reducing Structural Barriers	Assistance with Postage Costs*	
Reducing Client Out-of-pocket costs,	Technical Assistance	
Provider Assessment & Feedback,		
Provider Reminder & Recall		
Systems		

*Based on availability



Resources for Colon Cancer Screening



Take a look inside.







60014 American Cancer Societa Inc. No. 030541



I survived colorectal ancer because I found it early.

Venice Family Clinic – Simms/Mann Health Center 2509 Pico Blvd. Santa Monica, CA 90405

a tiempo.







Reminder:

Colon and rectal cancer (called colorectal cancer) is the third most common cause of cancer death for men and women Fecal occult blood test/fecal immunochemical test (FOBT/RT) testing is one of several colorectal

cancer screening tests recommended by the American Cancer Society for adults without any symptoms. This testing should begin at age 50. By getting tested regularly, colorectal cancer car be found early when it is easier to treat.

- Our records show you are due for your colorectal cancer screening.
- Our records show you have not returned your FOBT/FIT colorectal cancer screening test kit.

To schedule an appointment or for information on completing your FOBT/FIT kit, please call 310-392-8636

Recordatorio:

El cáncer de colon y de recto (llamado cáncer colorrectal) es la tercera causa principal de muerte por cáncer en los hombres y las mujeres.

Prueba de sangre oculta en las heces fecales / Prueba inmunoquímica fecal (FOBT/FIT) son unos de los diversos exámenes de detección de cáncer colorrectal recomendados por la Sociedad

- Americana Contra El Cáncer para los adultos que no presentan síntomas. Este examen debe comenzar a los 50 años. Si se hace los exámenes regularmente, el cáncer colorrectal puede ser detectado a tiempo cuando es más fácil tratarlo.
- Nuestros registros indican que a usted le corresponde realizarse un examen de câncer colorrectal
- Nuestros registros indican que no ha devueito la prueba de FOBT/RT cuyo objetivo es detectar el cáncer colorrectal.

Para hacer una cita o para obtener información acerca de cómo usar el paquete de FOBT/FIT, llame a 310-392-8636

*Poster



You can help *prevent* colon cancer.

If you're 50 or older, talk to your doctor about getting screened for colon cancer.

Colon cancer is the second-leading cause of cancer death in the US when men and women are combined, yet it can be prevented or found at an early stage, when it's small and easier to treat. Visit cancer.org/colon or call 1-800-227-2345 to learn more.






cancer.org | 1.800.227.2345 1,866,228,4327 TTY

@2016 American Cancer Society, Inc. No. 012813 Models used for illustrative purposes only

Recommended Evidence Based Interventions

Provider Assessment & Feedback

Assessing how many patients receive screenings and sharing feedback with providers using a scorecard or other tracking tool



Recommended Evidence Based Interventions


Provider Reminder & Recall Systems

Having reminders/recalls as part of the medical record Pre-Visit/Preventive Screening

General Measures (F				Den Dishoton Datis	anto	Orde	
Has the patient had a t		0		Second se			
			Has the patient had a tetanus vaccine within the last 10 years? Yes		If pre-diabetic, has the patient had a HgbA1c test within the last year?		
	06/02/2005	Order Te	tanus	Date of Last	10/29/2011	Order	
Has the patient had a f	fu vaccine within the last year?		Yes	Diabetes Patients			
Date of Last	10/19/2011	Order Fi	u Shot		d a HgbA1c within the	e kust your?	
	ad a poeumonia abot? (Age>50)		N/A	Date of Last	10/29/2011		
Date of Last	01/26/2005	Order Pne		Has the patient ha	d a dialed eye exam	within the last your?	
The second s	an elevated (>100 mgell.) LDL?		Yes	Date of Last	02/03/2011	Add Re	
Last 113	09/21/2011	Order Lipi		Has the patient ha	d a 10-gram monofilm	ment exam within the last year?	
	and the second se	Section of the sectio	aller the	Date of Last	08/24/2011		
and a state of the	creened at least once for HIV?	in the second seco	Yes	Has the patient ha	d screening for nephr	ropathy within the last year?	
Outer of Last	07/27/2011	Order HIV	Screen	Date of Last	08/18/2010		
	if patient refused or if positive of	Sagnosis previously o	onfirmed.	Has the patient ba	d a unnalysis within th	ter last vent?	
Click If Pat	ient Refuses Testing			Date of Last	07/07/2011		
Elderly Patients (Patie Has the patient had an	ents >65) eccuit blood test within the last	year? (Patients >50)	N/A	Has the patient ev been referred to D	ISWE7	Has the patient been referred to DSME within the last two years?	
Date of Last	11			Female Patients	Add Rel	ferrals Below	
	all risk assessment completed v	within the last year?	N/A		d a pap smear within	the last two years? (Ages 21 to 64)	
Date of Last	01/09/2012		land and the second sec	Date of Lant	11	Add Rt	
	functional assessment within the	Same unar?	N/A	Has the patient ha	d a mamnogram with	n the last two years? (Ages 40 to 69	
	04/01/2011	ran year		Date of Last	11	Add Re	
Date of Last			N/A	Has the pabent ha		in the last two years? (Age >50)	
	pain screening within the last ye	ar?	R/A	Date of Lust	03/27/2009	Add Re	
Date of Last	04/01/2011			Male Patients			
Has the patient had a g	glaucoma screen (diated exam)	within the last year?	N/A	Has the patient ha	d a PSA within the las		
Date of Last	02/03/2011	Add Referru	I At Right	Date of Last	04/02/2007	Ord	
Does the patient have discussed with the patient the patient of t	advanced directives on file or h tient?	ave they been	N/A	Has the patient ha	d a bone density with 03/27/2009	in the last two years? (Age >65) Add Re	
Discussed?	Completed?					7002100	
	more medications which are cr	insidered high risk	N/A		le-Click To Add/Edit)	le e i	
in the elderly?				Referral	Status	Referring	

Other Areas of Support

Work with QI Team to do Process Mapping/Flow



Sample Office Policy Worksheet: What is Everyone's Role? While in the Waiting Room Ask the patient to complete a questionnaire to provide information on risk, status, screening history, and attitudes. · Place informative and attractive posters or fliers in the waiting room or exam rooms as an expression of your own policy and as cues to action. · Customize the use of educational instructional materials, and reminder tools to suit your practice needs. Enter staff responsible here: Have staff ask about preventive care and highlight services that are needed or past due. · Use preventive care flow sheets and reminder chart stickers. During the Visit · Ask patients about family history and previous screening. Let your patients know that getting CRC screening can prevent cancer and save lives.

· Schedule screening before the patients leaves the office.

Enter staff responsible here:

This chart can be viewed at: <u>http://www.cancer.org/acs/groups/content/documents/document/acspc-024588.pdf</u> - Page 47

Other Areas of Support


 Coordinate Physician Speakers on Colorectal and Breast Cancer Screening and HPV Vaccination to present to providers.




Primary Care Tools We Offer

Implementation Guides & Manuals









EIGHTY BY 2018

R





Resources

- American Cancer Society
 - www.cancer.org/colonmd
 - www.cancer.org/professionals
 - Colorectal Cancer Facts and Figures 2014 2016: <u>http://www.cancer.org/acs/groups/content/d</u> <u>ocuments/document/acspc-042280.pdf</u>
- National Colorectal Cancer Roundtable
 - www.nccrt.org
- Flu-FIT
 - www.flufit.org



THANK YOU!

Jessica Jamison, MPH Jessica.Jamison@cancer.org 510.464.8202

